Ireland-based Covidien has received CE mark approval for its Nellcor bedside SpO2 patient monitoring system, PM100N.
According to the company, the system is the only commercially available bedside pulse oximetry (SpO2) monitor featuring home care and sleep study modes.
The system is said to provide continuous monitoring of blood oxygenation (SpO2) and pulse rate. It allows clinicians to detect dangerous respiratory events and patient trend data sooner to evaluate clinical course.
PM100N features SatSeconds Alarm Management technology that helps in distinguishing serious and minor events. It is available only on Covidien patient monitors, which is password-protected to prevent lay users from inadvertently modifying settings.
Covidien respiratory and monitoring solutions chief medical officer Dr Scott Kelley said: "The availability of solutions to enable safe, quality care for patients in all settings, including the home, is something we are focused on at Covidien.
"This new system includes all of the leading Nellcor technology that clinicians have trusted for more than 30 years, with additional features that make it well suited to the home health care environment."
Currently, the system is available for sale in the European Economic Area (EEA), Australia and New Zealand.
Covidien, which reported $10.7bn revenue in 2014, operates in around 150 countries.
Image: Covidien’s manufacturing facility in Galway, Ireland. Photo: courtesy of Covidien.